Craft
  • Home
  •  / Acceleron Pharma
Acceleron Pharma

Acceleron Pharma

Patents Issued

788

FY, 2019

Revenue

$92.5 M

FY, 2020

Market Capitalization

$10.6 B

2021-11-12

Acceleron Pharma Summary

Company summary

Overview
Acceleron Pharma is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of treatments for hematologic, neuromuscular, and pulmonary diseases. The company specializes in TGF-beta biology and protein engineering to regulate cellular growth and repair.
Type
Public
Founded
2003
HQ
Cambridge, MA, US | view all locations
Website
http://www.acceleronpharma.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Habib Dable

    Habib Dable, President, Chief Executive Officer

  • Kevin McLaughlin

    Kevin McLaughlin, Senior Vice President and Chief Financial Officer

  • Jay T. Backstrom

    Jay T. Backstrom, Executive Vice President, Head of Research and Development

    • James Desiderio

      James Desiderio, Senior Vice President, Regulatory and Quality

    Operating MetricsView all

    Patent Applications

    637
    26.1%

    FY, 2019

    Patents Issued

    788
    11.3%

    FY, 2019

    LocationsView all

    2 locations detected

    • Cambridge, MA HQ

      United States

      128 Sidney St

    • Zug, ZG

      Switzerland

      Grafenauweg 8

    Acceleron Pharma Financials

    Summary financials

    Cash (Q3, 2021)
    $336.5M

    Footer menu